Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the latest ESG scores for the first round of participating companies. Hansoh Pharma received a score of 63 points, compared with 40 points in 2021, up over 57%，making another significant improvement while maintaining its leadership in China's pharmaceutical industry.
S&P Global CSA is one of the world's largest annual assessments of corporate sustainability practices initiated by S&P Global, and rigorously identifies companies that are better equipped to recognize and respond to emerging sustainability opportunities and challenges through a comprehensive review of ESG governance areas such as corporate economy, environment, social responsibility and governance. This significant increase in Hansoh Pharma's CSA score fully demonstrates the company's firm belief and outstanding achievement in adhering to its sustainable development strategy and integrating ESG governance into its business management.
High recognition for practicing ESG commitment on multiple issues
In this year's CSA scoring, Hansoh Pharma had significant improvements over last year in the key categories of Risk and Crisis Management, Anti-Competition and Business Ethics, Supply Chain Management, Information Security, Innovation Management, Climate Change Strategy, Strategic Talent Planning and Motivation, and Inclusive Healthcare, and received full marks on the issues of Code of Conduct on Business Ethics, Supply Chain Risk Management to Ensure Stable Supply of Key Materials, Climate Change Strategy to Proactively Respond to China's Carbon Peaking by 2030 and Carbon Neutrality by 2060 Goals, and Pharmacoeconomic Evaluation to Improve Affordability. This result fully reflects Hansoh Pharma's efforts and achievements in the field of ESG governance in recent years, which have received high recognition from international authoritative organizations.
It is noteworthy that Hansoh Pharma has received a high CSA mark on the issue of "Product Safety and Quality Management" for two consecutive years. In order to effectively fulfill its health commitment, Hansoh Pharma insists on product quality and safety as the cornerstone of development, and relies on a quality management system that covers the whole process of production and operation and the whole life cycle of products to fully ensure the quality and safety of products and guard the life and health of patients.
On social issues whose main indicators include Employee Development and Charity, Hansoh Pharma achieved the largest increase in this CSA scoring. For a long time, Hansoh Pharma has been adhering to the development approach of "Advance, Create, Commit and Share Together", taking active steps to establish an industry-competitive compensation and benefits system, further improving its training and growth mechanism, and fully combining employee growth and company development. While promoting steady development of the company, Hansoh Pharma has been devoting itself to charity programs such as Covid prevention and control, caring for medical personnel and helping the elderly with a high sense of social responsibility and mission, in an effort to give back to the community and contribute to the Health China 2030 initiative.
Continuous improvement of ESG Management System towards more efficient and sustainable development
Opportunities and challenges coexist; breakthroughs and innovations go hand in hand. While focusing on its own development, Hansoh Pharma has made substantial progress through ESG management and practice and kept creating value for the sustainable development of society.
To keep ESG governance aligned with international standards, Hansoh Pharma has established an Environmental, Social and Governance Committee under its Board of Directors on the basis of UN SDGs, TCFD recommendations and mainstream ESG governance frameworks, and has incorporated ESG into its overall strategic planning to ensure the effective implementation and sustainable execution of work at all levels. Based on the outstanding results of ESG performance management, Hansoh Pharma's MSCI ESG rating has been upgraded for two consecutive years and has been included in the HSCEI ESG Index.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma adheres to its sustainable business philosophy, further improves its policies and systems, and continuously improves its ESG management system, including governance structure and strategy, product safety and quality, human resources and development, environmental protection and social responsibility, so as to build momentum for its global innovation and development. The company always puts patients in the first place, strengthens the drive for technological innovation, and keeps introducing innovative drugs and breakthrough therapies with greater safety, efficacy and affordability, in an effort to bring more innovative medical solutions to patients in China and around the world.
About Hansoh Pharma
Founded in 1995, Hansoh Pharmaceutical Group Company Limited, the main business entity of Hansoh Pharma, is a leading innovation-driven pharmaceutical company in China. Adhering to the corporate mission to create excellence in pharmaceuticals and enhance innovation in China, Hansoh Pharma focuses on the treatment of oncology, infection, CNS, metabolism and autoimmunity diseases, and is committed to improving human health through continuous innovation. Up to now, Hansoh Pharma has marketed six innovative drugs and formed a rich pipeline, ranked among the top 30 of China's Top 100 Companies in Pharmaceutical Industry and the top 3 of China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for consecutive years. It is a national key high-tech enterprise and national technology innovation demonstration enterprise. Hansoh Pharma went public on the Stock Exchange of Hong Kong Ltd. in June 2019 (SEHK: 3692).
About S&P Global (CSA) ESG Scores
S&P Global CSA ESG Scores are rooted in the highly recognized S&P Global Corporate Sustainability Assessment (CSA), an annual assessment to rigorously identify companies that are better equipped to recognize and respond to emerging sustainability opportunities and challenges through a comprehensive review of their ESG performance. Backed by 20 years of investment performance data, the S&P Global Global CSA research methodology is characterized by thoroughness and granularity, rigorous standards for verification, and data source transparency. Conducted annually, the assessment intends to identify companies that are better equipped to recognize and respond to emerging sustainability opportunities and challenges.
